We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to Know
Read MoreHide Full Article
Amgen (AMGN - Free Report) closed the most recent trading day at $460.73, moving +1.97% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 0.31% for the day. At the same time, the Dow lost 0.25%, and the tech-heavy Nasdaq lost 1.38%.
Shares of the world's largest biotech drugmaker witnessed a gain of 7.19% over the previous month, beating the performance of the Medical sector with its gain of 2.58%, and the S&P 500's gain of 0.87%.
Investors will be eagerly watching for the performance of Amgen in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 3, 2026. The company is predicted to post an EPS of $5.74, indicating a 1.77% growth compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.95 billion, up 4.14% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $22.96 per share and a revenue of $38.86 billion, indicating changes of +5.13% and +5.74%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Amgen. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.08% higher within the past month. Amgen is currently sporting a Zacks Rank of #3 (Hold).
With respect to valuation, Amgen is currently being traded at a Forward P/E ratio of 19.68. This indicates a discount in contrast to its industry's Forward P/E of 25.4.
Also, we should mention that AMGN has a PEG ratio of 3.31. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.9.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 98, this industry ranks in the top 40% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to Know
Amgen (AMGN - Free Report) closed the most recent trading day at $460.73, moving +1.97% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 0.31% for the day. At the same time, the Dow lost 0.25%, and the tech-heavy Nasdaq lost 1.38%.
Shares of the world's largest biotech drugmaker witnessed a gain of 7.19% over the previous month, beating the performance of the Medical sector with its gain of 2.58%, and the S&P 500's gain of 0.87%.
Investors will be eagerly watching for the performance of Amgen in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 3, 2026. The company is predicted to post an EPS of $5.74, indicating a 1.77% growth compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.95 billion, up 4.14% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $22.96 per share and a revenue of $38.86 billion, indicating changes of +5.13% and +5.74%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Amgen. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.08% higher within the past month. Amgen is currently sporting a Zacks Rank of #3 (Hold).
With respect to valuation, Amgen is currently being traded at a Forward P/E ratio of 19.68. This indicates a discount in contrast to its industry's Forward P/E of 25.4.
Also, we should mention that AMGN has a PEG ratio of 3.31. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.9.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 98, this industry ranks in the top 40% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.